rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GOSS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Gossamer Bio is Chardan's top small-cap pick for 2027
      Nov 11Seeking AlphaGOSS
      Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
      Nov 11BenzingaGOSS
      Wedbush cuts Gossamer Bio stock price target on regulatory uncertainty
      Nov 11Investing.comGOSS
      Gossamer Bio earnings missed by $3.57, revenue topped estimates
      Nov 11Investing.comGOSS
      Gossamer Bio: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceGOSS
      Gossamer Bio Shareholders Approve Major Stock Issuance Plan

      Tipranks Press Release.

      Oct 29The Globe and MailGOSS
      Chardan reiterates Gossamer Bio stock rating on PAH drug outlook
      Oct 26Investing.comGOSS
      Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks
      Oct 17Yahoo FinanceGOSS
      Chardan initiates Gossamer Bio stock with buy on PAH therapy potential
      Oct 13Investing.comGOSS
      Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

      Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...

      Oct 1Yahoo FinanceGOSS
      Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS)

      Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

      Sep 25The Globe and MailGOSS
      Gossamer Bio Files New Drug Application for Seralutinib

      Gossamer Bio (GOSS) said late Wednesday it has submitted a new drug application to the US Food and D

      Sep 23Yahoo FinanceGOSS
      Gossamer Bio stock rises on FDA filing for PAH drug
      Sep 23Investing.comGOSS
      Gossamer Bio submits NDA for seralutinib in PAH treatment
      Sep 23Investing.comGOSS
      Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

      SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme

      Sep 23Yahoo FinanceGOSS
      Gossamer Bio Adds Veteran Investor to Board of Directors

      Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailGOSS
      Gossamer Bio Appoints Greg Ciongoli to Board of Directors

      SAN DIEGO, September 16, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.

      Sep 16Yahoo FinanceGOSS
      Gossamer Bio completes 1-for-80 reverse stock split
      Sep 11Investing.comGOSS
      Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
      Sep 11Yahoo FinanceGOSS
      Gossamer Bio at Cantor Fitzgerald healthcare conference: filing path in focus
      Sep 9Investing.comGOSS
      Gossamer Bio Announces 1-for-80 Reverse Stock Split
      Sep 9Yahoo FinanceGOSS
      Gossamer Bio to Present at Cantor Global Healthcare Conference

      SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.

      Sep 4Yahoo FinanceGOSS
      Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

      Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financing into three stages, leaving most of the headline amount dependent on regulatory milestones. At the initial closing, Gossamer Bio, Inc. (NASDAQ:GOSS) expects approximately $25 […]

      Aug 27Yahoo FinanceGOSS
      H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress
      Aug 27Investing.comGOSS
      Gossamer Bio announces $250m in funding to advance seralutinib

      The proceeds will help advance seralutinib's clinical development and potential commercialisation.

      Aug 24Yahoo FinanceGOSS
      Gossamer Bio Slips as $250M Financing Hinges on FDA Approval - Gossamer Bio (NASDAQ:GOSS)
      Aug 21BenzingaGOSS
      Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

      Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.

      Aug 21Yahoo FinanceGOSS
      Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

      Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a

      Aug 21Yahoo FinanceGOSS
      Gossamer Bio secures up to $250m in milestone-based financing
      Aug 21Investing.comGOSS
      Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

      SAN DIEGO, August 21, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing e

      Aug 21Yahoo FinanceGOSS

      This is the newest page. Registered accounts read further back.